Wednesday, October 14, 2026

The Oasis Group's Dual Consulting and Ratings Role Raises Independence Questions

The Oasis Group, publisher of the 2026 Peaks for Estate Planning Platforms report, operates simultaneously as a ratings publisher and consulting firm. A risk assessment flags a major conflict-of-interest concern: vendors rated in its reports may also be paying consulting clients or sponsors. The likelihood is assessed as low, but the structural overlap persists.

LM Salvado
LM Salvado

May 31, 2026

The Oasis Group's Dual Consulting and Ratings Role Raises Independence Questions
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The Oasis Group publishes vendor ratings in the wealth management and estate planning sectors while also selling consulting services to firms in the same market.1 That dual role creates a governance vulnerability that analysts have flagged as a major operational risk.

The firm is best known as the publisher of the 2026 Peaks for Estate Planning Platforms report, a widely referenced benchmark in fintech and estate planning circles.1 It also operates across wealth management research, market analysis, and consulting — domains that overlap directly with the vendors it rates.

The core concern: a firm that earns consulting revenue or sponsorship fees from vendors it simultaneously rates cannot credibly guarantee independence in its assessments.1 Even where editorial controls exist, the financial relationship creates a structural conflict that undermines trust in ratings outcomes.

This is not a new problem in financial research. Credit rating agencies faced parallel criticism after the 2008 financial crisis, when issuers paid directly for their own ratings. The lesson — that pay-to-rate models corrupt incentive structures — has since shaped regulatory frameworks for traditional ratings bodies. Independent research firms occupy a less regulated space, making self-imposed governance the primary safeguard.

The risk assessment places severity at major.1 Likelihood is rated low, reflecting that no specific incident has been identified. But low likelihood does not neutralize a major-severity structural exposure. It means the conditions for a conflict exist; it does not mean none has occurred.

For institutional clients relying on The Oasis Group's rankings to make platform procurement or investment decisions, the question is practical: are the ratings independent, and how is that independence verified? Without published disclosure of client relationships, firewall policies, or third-party audits, that question remains open.

Governance best practice in research publishing requires affirmative separation between commercial and editorial functions — separate teams, disclosed conflicts, and ideally independent oversight. Whether The Oasis Group has implemented such controls is not publicly documented.

The wealth management sector relies heavily on third-party research to evaluate fintech vendors. Ratings credibility is the product. Any erosion of that credibility has direct consequences for both the firm's market position and the clients who act on its outputs.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com